 CAMBRIDGE, Mass., April 27, 2021 GLOBE NEWSWIRE -- Beam Therapeutics Inc. Nasdaq: BEAM, a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present data highlighting its proprietary base editing approach in several presentations during the 24th American Society of Gene and Cell Therapy ASGCT Annual Meeting, which will be hosted virtually May 11-14, 2021. In addition, Beam has been selected as a workshop presenter in the pre-meeting program taking place on May 10, 2021. 